“Inclisiran: Early LDL-C target achievement in a real-life population”
Atherosclerosis PlusBackground and objectives: Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with atherosclerotic cardiovascular diseases. Inclisiran, a small interfering RNA, has been observed to effectively and sustainably reduce LDL-C in ...
Francesco Briani +4 more
doaj +1 more source
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects [PDF]
, 2023 In 2003, clinical observations led to the discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism. Functional studies demonstrated that PCSK9 binds to the low-density lipoprotein (LDL) receptor directing ...
Gouni-Berthold, Ioanna +2 more
core +1 more source
The contribution of extracellular RNA and its derived biomaterials in disease management
BMEMat, Volume 3, Issue 2, June 2025.The implications of exRNA's biological function and the structural uniqueness of RNA help establish a close connection between RNA, material, and modern medicine. Abstract The RNA found in the circular system is known as extracellular RNA (exRNA). This kind of RNA has been found to play a biological role similar to that of a messenger. They can be used
Yu Wei +8 more
wiley +1 more source
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP) [PDF]
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe.
Bajraktari, Gani +31 more
core +4 more sources
Pooled Safety Analysis of Inclisiran in 3,576 Patients With Approximately 10,000 Person Years of Exposure From Seven Trials [PDF]
, 2023 Adam J. Nelson +11 more
openalex +1 more source
2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid. [PDF]
J Lipid AtherosclerInclisiran and bempedoic acid (BA) are non-statin lipid-lowering agents that have been approved for use in the US and Europe. Inclisiran, a subcutaneously administered small interfering RNA targeting proprotein convertase subtilisin/kexin type 9 ...
Kim HL +4 more
europepmc +2 more sources
Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study
Pharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.ABSTRACT Cardiovascular diseases are the leading cause of mortality worldwide, with dyslipidemia as a major modifiable risk factor. This study aimed to assess 25‐year trends in lipid‐lowering agent consumption in Croatia from 2000 to 2023. We conducted a population‐based analysis using IMS and IQVIA databases, calculating drug utilization in defined ...
Andrej Belančić +5 more
wiley +1 more source
Diabetic Medicine, Volume 42, Issue 6, June 2025.Abstract Aims Diabetes mellitus remains a prevalent condition worldwide and a significant risk factor for atherosclerotic cardiovascular disease. Recent evidence suggests the use of glucose‐lowering therapies with cardiovascular benefit in optimising the cardiometabolic profile of patients with type 2 diabetes mellitus.
Muhammad Usman Shah +6 more
wiley +1 more source
High risk cardiovascular disease:From insight to therapy [PDF]
, 2019 The last decades have witnessed tremendous progress in preventing and treating cardiovascular disease. Notably, the advent of statin therapy in the 1990s marks one of the victories of contemporary medicine.
Stoekenbroek, R.M.
core +2 more sources